1852 related articles for article (PubMed ID: 27237577)
1. Non-alcoholic fatty liver disease and dyslipidemia: An update.
Katsiki N; Mikhailidis DP; Mantzoros CS
Metabolism; 2016 Aug; 65(8):1109-23. PubMed ID: 27237577
[TBL] [Abstract][Full Text] [Related]
2. Hepatic Steatosis and Insulin Resistance, But Not Steatohepatitis, Promote Atherogenic Dyslipidemia in NAFLD.
Bril F; Sninsky JJ; Baca AM; Superko HR; Portillo Sanchez P; Biernacki D; Maximos M; Lomonaco R; Orsak B; Suman A; Weber MH; McPhaul MJ; Cusi K
J Clin Endocrinol Metab; 2016 Feb; 101(2):644-52. PubMed ID: 26672634
[TBL] [Abstract][Full Text] [Related]
3. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
Doumas M; Imprialos K; Stavropoulos K; Athyros VG
Curr Vasc Pharmacol; 2019; 17(5):425-428. PubMed ID: 31418344
[TBL] [Abstract][Full Text] [Related]
4. Addition of trans fat and alcohol has divergent effects on atherogenic diet-induced liver injury in rodent models of steatohepatitis.
Daniels SJ; Leeming DJ; Detlefsen S; Bruun MF; Hjuler ST; Henriksen K; Hein P; Krag A; Karsdal MA; Nielsen MJ; Brockbank S; Cruwys S
Am J Physiol Gastrointest Liver Physiol; 2020 Mar; 318(3):G410-G418. PubMed ID: 31905026
[TBL] [Abstract][Full Text] [Related]
5. Metabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
Asrih M; Jornayvaz FR
Mol Cell Endocrinol; 2015 Dec; 418 Pt 1():55-65. PubMed ID: 25724480
[TBL] [Abstract][Full Text] [Related]
6. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
7. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis.
Bellanti F; Villani R; Facciorusso A; Vendemiale G; Serviddio G
Free Radic Biol Med; 2017 Oct; 111():173-185. PubMed ID: 28109892
[TBL] [Abstract][Full Text] [Related]
8. Oxidized low-density lipoprotein antibodies/high-density lipoprotein cholesterol ratio is linked to advanced non-alcoholic fatty liver disease lean patients.
Ampuero J; Ranchal I; Gallego-Durán R; Pareja MJ; Del Campo JA; Pastor-Ramírez H; Rico MC; Picón R; Pastor L; García-Monzón C; Andrade R; Romero-Gómez M
J Gastroenterol Hepatol; 2016 Sep; 31(9):1611-8. PubMed ID: 26946071
[TBL] [Abstract][Full Text] [Related]
9. [Mechanism Analysis and Prevention of Pathogenesis of Nonalcoholic Steatohepatitis].
Nakajima T; Naito H
Nihon Eiseigaku Zasshi; 2015; 70(3):197-204. PubMed ID: 26411937
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
Simon TG; Corey KE; Chung RT; Giugliano R
Dig Dis Sci; 2016 Dec; 61(12):3425-3435. PubMed ID: 27714510
[TBL] [Abstract][Full Text] [Related]
11. Non-Alcoholic Fatty Liver Disease.
Engin A
Adv Exp Med Biol; 2017; 960():443-467. PubMed ID: 28585211
[TBL] [Abstract][Full Text] [Related]
12. Animal models of non-alcoholic fatty liver disease: current perspectives and recent advances.
Lau JK; Zhang X; Yu J
J Pathol; 2017 Jan; 241(1):36-44. PubMed ID: 27757953
[TBL] [Abstract][Full Text] [Related]
13. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
[TBL] [Abstract][Full Text] [Related]
14. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions.
Clemente MG; Mandato C; Poeta M; Vajro P
World J Gastroenterol; 2016 Sep; 22(36):8078-93. PubMed ID: 27688650
[TBL] [Abstract][Full Text] [Related]
15. Steatosis and NASH in type 2 diabetes.
Hu M; Phan F; Bourron O; Ferré P; Foufelle F
Biochimie; 2017 Dec; 143():37-41. PubMed ID: 29097281
[TBL] [Abstract][Full Text] [Related]
16. Serum vascular cell adhesion molecule-1 predicts significant liver fibrosis in non-alcoholic fatty liver disease.
Lefere S; Van de Velde F; Devisscher L; Bekaert M; Raevens S; Verhelst X; Van Nieuwenhove Y; Praet M; Hoorens A; Van Steenkiste C; Van Vlierberghe H; Lapauw B; Geerts A
Int J Obes (Lond); 2017 Aug; 41(8):1207-1213. PubMed ID: 28461687
[TBL] [Abstract][Full Text] [Related]
17. Discordant association of nonalcoholic fatty liver disease with lipoprotein(a) and markers of atherogenic dyslipidemia.
Mehta A; Lee TB; Alebna P; Grandhi GR; Dixon DL; Salloum FN; Sanyal AJ; Siddiqui MS
J Clin Lipidol; 2023; 17(6):828-833. PubMed ID: 37957050
[TBL] [Abstract][Full Text] [Related]
18. The clinical significance of insulin resistance in non-diabetic patients with early forms of non-alcoholic fatty liver disease.
Shipovskaya AA; Dudanova OP; Kurbatova IV
Ter Arkh; 2018 Aug; 90(8):63-68. PubMed ID: 30701940
[TBL] [Abstract][Full Text] [Related]
19. Metabolic-associated fatty liver disease and lipoprotein metabolism.
Heeren J; Scheja L
Mol Metab; 2021 Aug; 50():101238. PubMed ID: 33892169
[TBL] [Abstract][Full Text] [Related]
20. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
